Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Wagner S Brum"'
Autor:
Sara Laureen Bartels, C Elizabeth Shaaban, Wagner S Brum, Lindsay A Welikovitch, Royhaan Folarin, Adam Smith, ISTAART PIA to Elevate Early Career Researchers
Publikováno v:
PLoS ONE, Vol 17, Iss 11, p e0277470 (2022)
IntroductionThe World Health Organization recognizes dementia as a public health priority and highlights research as an action to respond to the consequences, with early career dementia researchers (ECDRs) representing the key driving force. Due to t
Externí odkaz:
https://doaj.org/article/fedc15b2fcfb41c8a03e858a7a89327c
Autor:
Anna Orduña Dolado, Erik Stomrud, Nicholas J. Ashton, Johanna Nilsson, Clara Quijano-Rubio, Alexander Jethwa, Wagner S. Brum, Ann Brinkmalm Westman, Henrik Zetterberg, Kaj Blennow, Shorena Janelidze, Oskar Hansson
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-10 (2024)
Abstract Background Studies suggest that cerebrospinal fluid (CSF) levels of amyloid-β (Aβ)42 and Aβ40 present a circadian rhythm. However sustained sampling of large volumes of CSF with indwelling intrathecal catheters used in most of these studi
Externí odkaz:
https://doaj.org/article/f78a34bbdde94bdab236ffea02e7059b
Autor:
Wagner S. Brum, Nicholas C. Cullen, Joseph Therriault, Shorena Janelidze, Nesrine Rahmouni, Jenna Stevenson, Stijn Servaes, Andrea L. Benedet, Eduardo R. Zimmer, Erik Stomrud, Sebastian Palmqvist, Henrik Zetterberg, Giovanni B. Frisoni, Nicholas J. Ashton, Kaj Blennow, Niklas Mattsson-Carlgren, Pedro Rosa-Neto, Oskar Hansson
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Blood-based biomarkers for screening may guide tau positrion emissition tomography (PET) scan referrals to optimize prognostic evaluation in Alzheimer’s disease. Plasma Aβ42/Aβ40, pTau181, pTau217, pTau231, NfL, and GFAP were measured al
Externí odkaz:
https://doaj.org/article/45431c464f6049b581c84b0d07def687
Autor:
Juan Lantero-Rodriguez, Gemma Salvadó, Anniina Snellman, Laia Montoliu-Gaya, Wagner S. Brum, Andrea L. Benedet, Niklas Mattsson-Carlgren, Pontus Tideman, Shorena Janelidze, Sebastian Palmqvist, Erik Stomrud, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Oskar Hansson
Publikováno v:
Molecular Neurodegeneration, Vol 19, Iss 1, Pp 1-22 (2024)
Abstract Background Novel phosphorylated-tau (p-tau) blood biomarkers (e.g., p-tau181, p-tau217 or p-tau231), are highly specific for Alzheimer’s disease (AD), and can track amyloid-β (Aβ) and tau pathology. However, because these biomarkers are
Externí odkaz:
https://doaj.org/article/1f03c4bcfa8843128bc55b3c29041416
Autor:
Juan Lantero-Rodriguez, Agathe Vrillon, Aida Fernández-Lebrero, Paula Ortiz-Romero, Anniina Snellman, Laia Montoliu-Gaya, Wagner S. Brum, Emmanuel Cognat, Julien Dumurgier, Albert Puig-Pijoan, Irene Navalpotro-Gómez, Greta García-Escobar, Thomas K. Karikari, Eugeen Vanmechelen, Nicholas J. Ashton, Henrik Zetterberg, Marc Suárez-Calvet, Claire Paquet, Kaj Blennow
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-15 (2023)
Abstract Background Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer’s disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient land
Externí odkaz:
https://doaj.org/article/77904aa0f595409998732159a64f7f99
Autor:
Fernando Gonzalez-Ortiz, Przemysław R. Kac, Wagner S. Brum, Henrik Zetterberg, Kaj Blennow, Thomas K. Karikari
Publikováno v:
Molecular Neurodegeneration, Vol 18, Iss 1, Pp 1-12 (2023)
Abstract As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected individuals, their families and caregivers, and healthcare systems. Although AD can be identified and diagnosed by cerebrospinal fluid or neuroimaging b
Externí odkaz:
https://doaj.org/article/a8484e52130d45238e7de04870ee642e
Autor:
Joel Simrén, Wagner S. Brum, Nicholas J. Ashton, Andrea L. Benedet, Thomas K. Karikari, Hlin Kvartsberg, Emma Sjons, Firoza Z. Lussier, Mira Chamoun, Jenna Stevenson, Robert Hopewell, Vanessa Pallen, Keqiang Ye, Tharick A. Pascoal, Henrik Zetterberg, Pedro Rosa-Neto, Kaj Blennow
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-12 (2022)
Abstract Introduction Cerebrospinal fluid (CSF) tau biomarkers are reliable diagnostic markers for Alzheimer’s disease (AD). However, their strong association with amyloid pathology may limit their reliability as specific markers of tau neurofibril
Externí odkaz:
https://doaj.org/article/696a39d2f58b4396bc056504a06b2bf9
Autor:
Laia Montoliu-Gaya, Daniel Alcolea, Nicholas J. Ashton, Jordi Pegueroles, Johannes Levin, Beatriz Bosch, Juan Lantero-Rodriguez, María Carmona-Iragui, Olivia Wagemann, Mircea Balasa, Przemyslaw Radoslaw Kac, Isabel Barroeta, Albert Lladó, Wagner S. Brum, Laura Videla, Fernando Gonzalez-Ortiz, Bessy Benejam, Javier José Arranz Martínez, Thomas K. Karikari, Georg Nübling, Alexandre Bejanin, Andrea L. Benedet, Rafael Blesa, Alberto Lleó, Kaj Blennow, Raquel Sánchez-Valle, Henrik Zetterberg, Juan Fortea
Publikováno v:
EBioMedicine, Vol 90, Iss , Pp 104547- (2023)
Summary: Background: The diagnosis of symptomatic Alzheimer's disease is a clinical challenge in adults with Down syndrome. Blood biomarkers would be of particular clinical importance in this population. The astrocytic Glial Fibrillary Acidic Protein
Externí odkaz:
https://doaj.org/article/dad91128d4b14536afd8f3589a5bcde9
Autor:
Andréa L. Benedet, Wagner S. Brum, Oskar Hansson, Alzheimer’s Disease Neuroimaging Initiative, Thomas K. Karikari, Eduardo R. Zimmer, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-11 (2022)
Abstract Background Plasma biomarkers for Alzheimer’s disease (AD) have broad potential as screening tools in primary care and disease-modifying trials. Detecting elevated amyloid-β (Aβ) pathology to support trial recruitment or initiating Aβ-ta
Externí odkaz:
https://doaj.org/article/d184ae0b8ce8493a969476b183ddb186
Autor:
Guilherme Povala, Bruna Bellaver, Marco Antônio De Bastiani, Wagner S. Brum, Pamela C. L. Ferreira, Andrei Bieger, Tharick A. Pascoal, Andrea L. Benedet, Diogo O. Souza, Ricardo M. Araujo, Bruno Zatt, Pedro Rosa-Neto, Eduardo R. Zimmer, for the Alzheimer’s Disease Neuroimaging Initiative
Publikováno v:
Cell & Bioscience, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract Background Changes in soluble amyloid-beta (Aβ) levels in cerebrospinal fluid (CSF) are detectable at early preclinical stages of Alzheimer’s disease (AD). However, whether Aβ levels can predict downstream AD pathological features in cog
Externí odkaz:
https://doaj.org/article/2d34afcff2224b4f905cbb59816241fa